NCT03051477
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with a known history or evidence of brain metastases; Patient who has had any prior treatment with Mistletoe (injection or infusion)
https://ClinicalTrials.gov/show/NCT03051477